Alzheimer Disease Clinical Trials in Phoenix, Arizona

10 studies are recruiting for alzheimer disease in Phoenix, Arizona right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

   This study is to test LHP588 in persons who have mild to moderate Alzheimer's disease (AD) who have shown progressive mental decline in the last year and who have P. gingivalis (Pg) infection. P. gingivalis infection has been linked to the development of dementia. LHP588 is designed to target the P…

   Stage

   Phase 2

   Ages

   55 to 80

   Site

   Banner Alzheimer's Institute, Phoenix, Arizona

   Locations

   38 in total

   Run by

   Lighthouse Pharmaceuticals, Inc.

   See if you can join NCT06847321 on ClinicalTrials.gov

2. Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

   This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.

   Stage

   Phase 2

   Ages

   55 to 90

   Site

   Local Institution - 0048, Phoenix, Arizona

   Locations

   78 in total

   Run by

   Celgene

   See if you can join NCT06808984 on ClinicalTrials.gov

3. A Study of AMDX-2011P in Participants With Alzheimer's Disease

   The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with Alzheimer's Disease (AD).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Associated Retina Consultants, Phoenix, Arizona

   Run by

   Amydis Inc.

   See if you can join NCT06514001 on ClinicalTrials.gov

4. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

   The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Banner Alzheimer's Institute, Phoenix, Arizona

   Locations

   293 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT06585787 on ClinicalTrials.gov

5. A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

   The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.

   Stage

   Phase 3

   Ages

   55 and older

   Site

   Banner Alzheimer's Institute, Phoenix, Arizona

   Locations

   59 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07602582 on ClinicalTrials.gov

6. [18F]PI-2620 Phase 3 Histopathological Study

   This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with [18F]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after de…

   Stage

   Phase 3

   Ages

   50 and older

   Site

   Barrow Neurological Institute, Phoenix, Arizona

   Locations

   25 in total

   Run by

   Lantheus Biosciences Ltd.

   See if you can join NCT05641688 on ClinicalTrials.gov

7. Trial-Ready Cohort-Down Syndrome (TRC-DS)

   The purpose of the Trial-Ready Cohort - Down Syndrome (TRC-DS) is to enroll 120 healthy adults with Down syndrome (DS), between the ages of 25-55, into a trial ready cohort (TRC), and up to 550 participants in total including co-enrolled in the Alzheimer Biomarkers Consortium - Down Syndrome (ABC-D…

   Stage

   Not phased

   Ages

   25 to 55

   Site

   Barrow Neurological Institute, Phoenix, Arizona

   Locations

   22 in total

   Run by

   University of Southern California

   See if you can join NCT04165109 on ClinicalTrials.gov

8. A SMART Trial of Adaptive Exercises to Optimize Aerobic-Fitness Responses

   The goal of this clinical trial is to test 6 months of aerobic exercise in older adults who are 65 years or older and have mild cognitive impairment (MCI) or probable/possible mild Alzheimer's Disease. The main questions it aims to answer are: * test the effects of aerobic exercise on aerobic fitne…

   Stage

   Not phased

   Ages

   65 and older

   Site

   Arizona State University, Phoenix, Arizona

   Run by

   Arizona State University

   See if you can join NCT05877196 on ClinicalTrials.gov

9. Early-Stage Partner in Care Living Alone Plus

   EPICLA+ (Early-Stage Partners in Care Living Alone Plus) is a research project designed to assist people with early-stage memory loss who live alone in the community by providing early-stage related education and skill-training sessions, held via Zoom, designed to reduce stress, enhance well-being,…

   Stage

   Not phased

   Ages

   60 and older

   Site

   Arizona State University, Phoenix, Arizona

   Run by

   Arizona State University

   See if you can join NCT06962111 on ClinicalTrials.gov

10. Repurposing Siponimod for Alzheimer's Disease

    Collaboration with multiple sclerosis (MS) specialty colleagues led us to formulate the central hypothesis that Siponimod could lower the rate of brain atrophy in Alzheimer's disease (AD) subjects. To test our central hypothesis, we will carry out an 18-month Phase II, double-blind, randomized, two…

    Stage

    Phase 2

    Ages

    50 to 85

    Site

    St. Joseph's Hospital and Medical Center, Phoenix, Arizona

    Run by

    St. Joseph's Hospital and Medical Center, Phoenix

    See if you can join NCT06639282 on ClinicalTrials.gov